Overall survival data underline Xtandi's dominance in prostate cancer

17 September 2021
pfizer_colour_new_large

At the annual congress of the European Society of Medical Oncology (ESMO 2021), Japan’s Astellas Pharma (TSE: 4503) and partner Pfizer (NYSE: PFE) are offering new data for Xtandi (enzalutamide).

Data from the Phase III ARCHES study show the androgen receptor blocker improved overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), compared with placebo.

In the test group, the risk of death was reduced by 34% at the time of the analysis, while median OS was not reached in either treatment group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical